Skip to main content

Ocriplasmin Ophthalmic Dosage

Applies to the following strengths: 0.5 mg/0.2 mL; 0.375 mg/0.3 mL

Usual Adult Dose for Vitreomacular Adhesion

0.125 mg (0.1 mL of the diluted solution) via intravitreal injection to the affected eye ONCE as a single dose


  • Each drug vial should only be used once and for the treatment of a single eye.
  • This drug should be administered by a qualified physician.
  • The manufacturer product information should be consulted regarding administration.

Use: Treatment of symptomatic vitreomacular adhesion

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.



This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

  • Repeated administration in the same eye is not recommended.
  • Perioperative antibiotic drops may be administered at the discretion of the treating ophthalmologist.

Storage requirements:
  • Freeze and store in the original package to protect from light.
  • Do not refreeze a vial once it has been thawed.

Reconstitution/preparation techniques:
  • Thaw at room temperature and dilute before use.
  • The manufacturer product information should be consulted.

  • Treatment in the contralateral eye is not recommended concurrently or within 7 days of the initial injection in order to monitor the post-injection course, including the potential for decreased vision in the injected eye.
  • As a therapeutic protein, this drug has immunogenicity potential but has not undergone evaluation in this area.
  • There are no clinical data on concomitant use with VEGF-inhibitors.

  • Immediately following the intravitreal injection, patients should be monitored for side effects such as intraocular inflammation/infection, elevation in intraocular pressure, and decrease in visual acuity.

Patient advice:
  • Seek immediate care from your eye doctor if you have any vision or eye problems such as redness, light sensitivity, pain, and vision change following the drug injection.
  • Do not drive or use machines directly following the drug injection as you may experience temporary vision problems. Promptly contact your eye doctor if your vision problems persist or become worse.

More about ocriplasmin ophthalmic

Patient resources

Other brands


Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.